The estimated Net Worth of Bradley J Ph D Bolzon is at least $134 Million dollars as of 19 July 2021. Bradley Bolzon owns over 10,000 units of CRISPR Therapeutics AG stock worth over $6,762,881 and over the last 11 years he sold CRSP stock worth over $127,603,849. In addition, he makes $0 as Independent Director at CRISPR Therapeutics AG.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Bradley Bolzon CRSP stock SEC Form 4 insiders trading
Bradley has made over 44 trades of the CRISPR Therapeutics AG stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 10,000 units of CRSP stock worth $1,264,300 on 19 July 2021.
The largest trade he's ever made was buying 894,736 units of CRISPR Therapeutics AG stock on 3 February 2020 worth over $16,999,984. On average, Bradley trades about 49,532 units every 42 days since 2014. As of 19 July 2021 he still owns at least 148,831 units of CRISPR Therapeutics AG stock.
You can see the complete history of Bradley Bolzon stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Bradley Bolzon biography
Dr. Bradley J. Bolzon Ph.D. serves as Independent Director of the Company. Dr. Bolzon currently serves as a Managing Director of Versant Venture Management, LLC, where he has been employed since May 2004. Additionally, Dr. Bolzon served as a member of the board of directors of Flexion Therapeutics, Inc., a pharmaceutical company, from its inception in 2007 to June 2014. From February 2000 to May 2004, Dr. Bolzon served as Executive Vice President, Global Head of Business Development, Licensing & Alliances of F. Hoffman-La Roche Ltd., a pharmaceutical company. Dr. Bolzon also formerly served as Head of Cardiovascular Research at Eli Lilly and Company. Dr. Bolzon received a Ph.D. in Pharmacology and an M.S. in Pharmacology from the University of Toronto. He continued with post-doctoral work at the University of Ottawa Heart Institute. Bolzon’s experience in the biopharmaceutical industry qualifies him to serve on our Board of Directors.
How old is Bradley Bolzon?
Bradley Bolzon is 60, he's been the Independent Director of CRISPR Therapeutics AG since 2013. There are 1 older and 14 younger executives at CRISPR Therapeutics AG. The oldest executive at CRISPR Therapeutics AG is Katherine High, 68, who is the Independent Director.
What's Bradley Bolzon's mailing address?
Bradley's mailing address filed with the SEC is C/O CRISPR THERAPEUTICS, INC., 610 MAIN STREET, CAMBRIDGE, MA, 02139.
Insiders trading at CRISPR Therapeutics AG
Over the last 8 years, insiders at CRISPR Therapeutics AG have traded over $284,003,967 worth of CRISPR Therapeutics AG stock and bought 3,347,446 units worth $53,410,590 . The most active insiders traders include Plc Gsk, Ali Behbahani, and Corp /De/ Celgene. On average, CRISPR Therapeutics AG executives and independent directors trade stock every 13 days with the average trade being worth of $2,405,548. The most recent stock trade was executed by Julianne Bruno on 20 June 2024, trading 7,000 units of CRSP stock currently worth $318,080.
What does CRISPR Therapeutics AG do?
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
What does CRISPR Therapeutics AG's logo look like?
Complete history of Bradley Bolzon stock trades at CRISPR Therapeutics AG, Flexion Therapeutics Inc, and Black Diamond Therapeutics Inc
CRISPR Therapeutics AG executives and stock owners
CRISPR Therapeutics AG executives and other stock owners filed with the SEC include:
-
Samarth Kulkarni,
Chief Executive Officer, Director -
Lawrence Klein,
Chief Operating Officer, Chief Business Officer -
Tony Ho,
Executive Vice President - Research and Development -
James Kasinger,
General Counsel, Secretary -
Michael Tomsicek,
Chief Financial Officer -
Dr. Samarth Kulkarni,
CEO & Director -
Dr. Lawrence Otto Klein Ph.D.,
Chief Operating Officer -
James R. Kasinger,
Gen. Counsel & Sec. -
Rodger Novak,
Chairman of the Board, President, Co-Founder -
Dr. Rodger Novak M.D.,
Founder, Chairman & Pres -
Susan Kim,
IR Contact Officer -
Katherine High,
Independent Director -
John Greene,
Independent Director -
Simeon George,
Independent Director -
Bradley Bolzon,
Independent Director -
Ali Behbahani,
Independent Director -
Dr. Daniel G. Anderson Ph.D.,
Scientific Founder & Advisory Board Member -
Dr. Matthew Porteus M.D., Ph.D.,
Scientific Founder & Advisory Board Member -
Dr. Chad Cowan Ph.D.,
Scientific Founder -
Dr. Craig C. Mello Ph.D.,
Scientific Founder & Advisory Board Member -
Dr. Emmanuelle Marie Charpentier,
Co-Founder & Scientific Advisory Board Member -
Shaun Foy,
Founder -
Aktiengesellschaft Bayer Gl...,
-
Tyler Dylan Hyde,
Chief Legal Officer -
Pablo J Cagnoni,
Director -
Venture Capital Iv, L.P.Ver...,
-
Harbor Master Investors (Ca...,
10% owner -
Kurt Von Emster,
Director -
Sven Ante Lundberg,
Chief Scientific Officer -
Corp /De/ Celgene,
10% owner -
Kala Subramanian,
See Remarks -
Thomas Woiwode,
Director -
N Anthony Coles,
Director -
Plc Gsk,
10% owner -
Pharmaceuticals (Europe) Lt...,
-
Venture Capital Iv, L.P.Ver...,
-
Julianne Bruno,
Chief Operating Officer -
Brendan Smith,
Chief Financial Officer -
Venture Capital Iv, L.P.Ver...,
-
Venture Capital V, L.P.Vers...,
-
Naimish Patel,
Chief Medical Officer -
Harold Edward Fleming,
-
Maria Fardis,
-
Sandesh Mahatme,
-
Douglas A Treco,
-
Christian Rommel,
-
Phuong Khanh Morrow,
Chief Medical Officer -
Raju Prasad,
Chief Financial Officer